<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03657290</url>
  </required_header>
  <id_info>
    <org_study_id>AKB-6548-CI-0028</org_study_id>
    <nct_id>NCT03657290</nct_id>
  </id_info>
  <brief_title>A Study in Evaluating Bioequivalence of Test and Reference Vadadustat 450 MG and 150 MG Tablets and to Determine Food Effect on the 450 MG Tablet</brief_title>
  <official_title>A Randomized, Open-Label, Single-Dose, Three-Period Six-Sequence Crossover Study in Healthy Adults to Assess Bioequivalence Between Test and Reference Vadadustat 450 mg and 150 mg Tablets and to Determine Food Effect on the 450 mg Vadadustat Tablet.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akebia Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akebia Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a healthy volunteers study to assess the bioequivalence of vadadustat 450 mg tablets
      (Test A) compared to three 150mg tablets (Reference B). The study will also assess the effect
      of food on the bioavailability of vadadustat 450 mg tablet.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open-label, single-dose, three-period crossover study in healthy adults
      to assess the bioequivalence of 3 X 150 mg vadadustat tablets (Test) compared to a single 450
      mg vadadustat tablet (reference). Blood samples for vadadustat PK will be collected at
      pre-dose (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12, 18, 24, 32, 40, and 48
      hours post-dose. The study will also assess the effect of food on vadadustat bioavailability
      by evaluating the pharmacokinetics of the 450 mg tablet in fed and fasted subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 3, 2018</start_date>
  <completion_date type="Actual">October 16, 2018</completion_date>
  <primary_completion_date type="Actual">October 16, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a randomized, open-label, single-dose, three-period, six- sequence crossover study in healthy adults. A total of 54 eligible subjects will be randomized to one of six treatment sequences (ABC, ACB, BAC, BCA, CAB, or CBA). Refer to Treatment Sequences below. Each sequence is comprised of 3 treatments</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence - Area under plasma concentration-time curve from 0 to last quantifiable concentration (AUClast)</measure>
    <time_frame>Baseline visit, 48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence - Area under plasma concentration-time curve from 0 to infinity (AUCinf)</measure>
    <time_frame>Baseline visit, 48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence - Area under plasma concentration-time curve from 0 to last sampling point (AUCall)</measure>
    <time_frame>Baseline visit, 48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence - Observed Maximum concentration (Cmax)</measure>
    <time_frame>Baseline visit, 48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure Food Effect - Area under plasma concentration-time curve from 0 to last quantifiable concentration (AUClast)</measure>
    <time_frame>Baseline visit, 48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure Food Effect - 2. Area under plasma concentration-time curve from 0 to infinity (AUCinf)</measure>
    <time_frame>Baseline visit, 48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure Food Effect - 2.3. Observed Maximum concentration (Cmax)</measure>
    <time_frame>Baseline visit, 48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax</measure>
    <time_frame>Baseline visit, 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Tmax</measure>
    <time_frame>Baseline visit, 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time (MRT)</measure>
    <time_frame>Baseline visit, 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination rate constant (Kel)</measure>
    <time_frame>Baseline visit, 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance (CL/F)</measure>
    <time_frame>Baseline visit, 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vd/F)</measure>
    <time_frame>Baseline visit, 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2)</measure>
    <time_frame>Baseline visit, 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of extrapolated area under the curve from time t to infinity (AUCextrap or Residual Area)</measure>
    <time_frame>Baseline visit, 48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>vadadustat 3 X 150 mg Tablets in fasted subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vadadustat 1 X 450 mg Tablets in fasted subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>vadadustat 1 X 450 mg Tablets in fed subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vadadustat</intervention_name>
    <description>Vadadustat Tablets</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <other_name>AKB-6548</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects between ≥18 years and ≤55 years of age

          -  Healthy subjects per Investigator judgment as documented by the medical history,
             physical examination, vital sign assessments, 12-lead electrocardiogram (ECG),
             clinical laboratory assessments, and general observations.

          -  Have a body weight ≥50 kg and body mass index (BMI) ≥18.5 kg/m2 to 29.5 kg/m2
             inclusive

          -  Understands the procedures, provides ICF and willing to comply with study requirements

          -  Willing and able to comply with the requirements of the study protocol.

        Exclusion Criteria:

          -  Current or past history of cardiovascular, cerebrovascular, pulmonary,
             gastrointestinal, hematologic, renal, hepatic, immunologic, metabolic, urologic,
             neurologic, dermatologic, psychiatric, or other major disease.

          -  History of cancer (except non- melanoma skin cancer) or history of chemotherapy use.

          -  Any surgical or medical condition or history that may potentially alter the
             absorption, metabolism, or excretion of study treatment, such as, but not limited to
             gastric bypass surgery or gastric or duodenal ulcers.

          -  History of severe allergic or anaphylactic reactions. Chronic daily medication use.

          -  History of drug abuse Excessive alcohol consumption.

          -  Smoking and the use of nicotine-containing products

          -  Consumption of grapefruit or grapefruit juice, pomelo, star fruit, Seville or Moro
             (blood) orange, or their associated products

          -  Participation in another clinical trial or exposure to any investigational agent.

          -  Donation of blood or significant blood loss or plasma donation.

          -  Any condition that would interfere with the ability to provide informed consent,
             comply with study instructions, or which might confound the interpretation of the
             study results or put the patient at undue risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Akebia Therapeutics</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Paraxel International</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>August 31, 2018</study_first_submitted>
  <study_first_submitted_qc>September 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2018</study_first_posted>
  <last_update_submitted>March 20, 2019</last_update_submitted>
  <last_update_submitted_qc>March 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vadadustat</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>bioequivalence</keyword>
  <keyword>pharmacokinetics</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

